Icelandic Coronary Event Register (Iceland)
Database Contact Data
Holtasmári 1, 2. floor
201 Kópavogur
ICELAND
Phone: +354 535-1800
Fax: +354 535-1801
Email: afgreidsla@hjarta.is
Alternate Contact
Email: johannag@hjarta.is
References of Studies Using/Describing Database
1. Aspelund T, Thorgeirsson G, Sigurdsson G, Gudnason V. Estimation of 10-year risk of fatal cardiovascular disease and coronary heart disease in Iceland with results comparable with those of the Systematic Coronary Risk Evaluation project. Eur J Cardiovasc Prev Rehabil. 2007 Dec;14(6):761-8.
2. Aspelund T, Gudnason V, Magnusdottir BT, Andersen K, Sigurdsson G, Thorsson B, Steingrimsdottir L, Critchley J, Bennett K, O'Flaherty M, Capewell S. Analysing the large decline in coronary heart disease mortality in the Icelandic population aged 25-74 between the years 1981 and 2006. PLoS One. 2010 Nov 12;5(11):e13957.
3. Andresdottir MB, Sigfusson N, Sigvaldason H, Gudnason V. Erythrocyte sedimentation rate, an independent predictor of coronary heart disease in men and women: The Reykjavik Study. Am J Epidemiol. 2003 Nov 1;158(9):844-51.
4. Sigfusson N, Sigurdsson G, Agnarsson U, Gudmundsdottir II, Stefansdottir I, Sigvaldason H, Gudnason V. Declining coronary heart disease mortality in Iceland: contribution by incidence, recurrence and case fatality rate. Scand Cardiovasc J. 2002 Dec;36(6):337-41.
5. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation. 1994 Jul;90(1):583-612.
Feb 17, 2023: B.R.I.D.G.E. is now starting its 15th year & offering a unique discount through March 2023!
B.R.I.D.G.E. TO DATA® is the most recent and updated version of the RAD-AR (Risk Assessment of Drugs-
Feb 14, 2023: We now have the Estonian Drug Treatment Register profile for you
The Estonian Drug Treatment Register was established in 2020. All health care providers treating drug dependence are required to send notification to the Register when starting or finishing a treatment episode. Each record contains personal identifiers (name and unique ID-code assigned to all residents of Estonia), socio-demographic characteristics, drugs used, date and code of diagnosis (ICD-10), as well as data on treatment episode.
Estonian Drug Treatment Register (Estonia)
Database Contact Data
Kersti Villand
Estonian Drug Treatment Register
National Institute for Health Development
Paldiski mnt 80
10617 Tallinn
ESTONIA
Email: kersti.villand@tai.ee
Alternate Contact
Estonian Drug Treatment Register
National Institute for Health Development
Paldiski mnt 80
10617 Tallinn
ESTONIA
Phone: +372 659 3900
Email 1: tai@tai.ee
Email 2: naris@tai.ee
References of Studies Using/Describing Database
N/A
Feb 9, 2023: Our 14th profile from Sweden has been uploaded
The Registry for Monitoring Fetal Damage and Chromosomal Abnormalities contains information on birth defects since 1964. Data from the Swedish Medical Birth Register are available since 1973, and data from the Swedish Patient Register are available since 1987. This specific register contains information on newborns, live births and stillborn children, who have a gestational age of at least 22 completed weeks of pregnancy and who have congenital malformations, deformities and chromosomal abnormalities.
National Register of Congenital Anomalies (Sweden)
Database Contact Data
SOCIALSTYRELSEN
The National Board of Health and Welfare
Department of Registers and Statistics
SE-106 30 Stockholm
SWEDEN
Phone: +46 75 247 30 00
Email: E-mail address: RELA@socialstyrelsen.se
References of Studies Using/Describing Database
1. Segovia Chacón S, Karlsson P, Cesta CE. Detection of major congenital malformations depends on length of follow-up in Swedish National Health Register Data: Implications for pharmacoepidemiological research on medication safety in pregnancy. Paediatr Perinat Epidemiol. 2024 Aug;38(6):521-531.
2. Gkekos L, Johansson ALV, Rodriguez-Wallberg KA, Fredriksson I, Lundberg FE. Obstetric and perinatal outcomes in women with previous breast cancer: a nationwide study of singleton births 1973-2017. Hum Reprod Open. 2024 May 4;2024(2):hoae027.
3. Caldeman C, Fogelström A, Oddsberg J, Mesas Burgos C, Löf Granström A. National birth prevalence, associated anomalies and mortality for gastroschisis in Sweden. Acta Paediatr. 2021 Sep;110(9):2635-2640.
4. Al-Jebari Y, Rylander L, Ståhl O, Giwercman A. Risk of Congenital Malformations in Children Born Before Paternal Cancer. JNCI Cancer Spectr. 2018 Jun 26;2(2):pky027.
5. Sabeti Rad Z, Friberg B, Henic E, Rylander L, Ståhl O, Källén B, Lingman G. Congenital malformations in offspring of women with a history of malignancy. Birth Defects Res. 2017 Feb 15;109(3):224-233.
6. Sabeti Rad Z, Friberg B, Henic E, Rylander L, Ståhl O, Källén B, Lingman G. Characteristics of the Offspring of Women with a History of Malignancy, Excluding Congenital Malformations. J Obstet Gynaecol Can. 2016 Nov;38(11):1037-1044.
7. Nikkilä A, Källén B, Marsál K. Fetal growth and congenital malformations. Ultrasound Obstet Gynecol. 2007 Mar;29(3):289-95.
8. Wennerholm UB, Bergh C, Hamberger L, Lundin K, Nilsson L, Wikland M, Källén B. Incidence of congenital malformations in children born after ICSI. Hum Reprod. 2000 Apr;15(4):944-8.
9. Kälién B, Robert E, Harris J. Associated malformations in infants and fetuses with upper or lower neural tube defects. Teratology. 1998 Feb;57(2):56-63.
10. Milerad J, Larson O, Hagberg C, Ideberg M. Associated malformations in infants with cleft lip and palate: a prospective, population-based study. Pediatrics. 1997 Aug;100(2 Pt 1):180-6.
Feb 7, 2023: Our latest profile addition from Estonia
With data since 1987, the Estonian Tuberculosis (TB) Register is a population-based, centralized national register with standardized registration of all TB cases in Estonia. This TB Register is an electronic, person-based one with unique personal Estonian ID-codes, linking data with the Estonian Population Register, TB reference laboratory database, and Causes of Death Register. All data are cross-checked with health care providers.
Estonian Tuberculosis Register (Estonia)
Database Contact Data
Katri Abel-Ollo
Estonian Tuberculosis Register
National Institute for Health Development
Hiiu 42
Tallinn 11619
ESTONIA
Email 1: Katri.Abel-Ollo@tai.ee
Email 2: tuberkuloosiregister@tai.ee
Phone: +372 659 39 17
Alternate Contact
Email: tai@tai.ee
Phone: +372 659 39 00
References of Studies Using/Describing Database
1. Schurz H, Naranbhai V, Yates TA, Gilchrist JJ, Parks T, Dodd PJ, Möller M, Hoal EG, Morris AP, Hill AVS; International Tuberculosis Host Genetics Consortium. Multi-ancestry meta-analysis of host genetic susceptibility to tuberculosis identifies shared genetic architecture. Elife. 2024 Jan 15;13:e84394.
2. Vasiliu A, Köhler N, Altpeter E, Ægisdóttir TR, Amerali M, de Oñate WA, Bakos Á, D'Amato S, Cirillo DM, van Crevel R, Davidaviciene E, Demuth I, Domínguez J, Duarte R, Günther G, Guthmann JP, Hatzianastasiou S, Holm LH, Herrador Z, Hribar U, Huberty C, Ibraim E, Jackson S, Jensenius M, Josefsdottir KS, Koch A, Korzeniewska-Kosela M, Kuksa L, Kunst H, Lienhardt C, Mahler B, Makek MJ, Muylle I, Normark J, Pace-Asciak A, Petrović G, Pieridou D, Russo G, Rzhepishevska O, Salzer HJF, Marques MS, Schmid D, Solovic I, Sukholytka M, Svetina P, Tyufekchieva M, Vasankari T, Viiklepp P, Villand K, Wallenfels J, Wesolowski S, Mandalakas AM, Martinez L, Zenner D, Lange C; TBnet. Tuberculosis incidence in foreign-born people residing in European countries in 2020. Euro Surveill. 2023 Oct;28(42):2300051.
3. Campbell JR, Chan ED, Falzon D, Trajman A, Keshavjee S, Leung CC, Miller AC, Monedero-Recuero I, Rodrigues DS, Seo H, Baghaei P, Udwadia Z, Viiklepp P, Bastos M, Menzies D. Low Body Mass Index at Treatment Initiation and Rifampicin-Resistant Tuberculosis Treatment Outcomes: An Individual Participant Data Meta-Analysis. Clin Infect Dis. 2022 Dec 19;75(12):2201-2210.
4. Cegielski JP, Chan PC, Lan Z, Udwadia ZF, Viiklepp P, Yim JJ, Menzies D. Aminoglycosides and Capreomycin in the Treatment of Multidrug-resistant Tuberculosis: Individual Patient Data Meta-analysis of 12 030 Patients From 25 Countries, 2009-2016. Clin Infect Dis. 2021 Dec 6;73(11):e3929-e3936.
5. Rahu K, Viiklepp P, Villand K, Pehme L, Rahu M. Respiratory tuberculosis incidence and mortality in Estonia: 30-year trends and sociodemographic determinants. Int J Tuberc Lung Dis. 2019 Jan 1;23(1):112-118.
6. Blöndal K, Rahu K, Altraja A, Viiklepp P, Rahu M. Overall and cause-specific mortality among patients with tuberculosis and multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2013 Jul;17(7):961-8.